Form 4: Arcus Biosciences CEO Sells Shares for Tax Obligations

Arcus Biosciences CEO Terry J. Rosen sold 54,691 shares of common stock over two days in December 2025 to cover tax withholding obligations related to RSU vesting, not as a discretionary trade.

Summary

• Terry J. Rosen, Chief Executive Officer and Director of Arcus Biosciences, Inc. (RCUS), reported the sale of 54,691 shares of common stock.
• The sales occurred on December 16, 2025, and December 17, 2025.
• On December 16, 2025, 28,947 shares were sold at a weighted average price of $21.8843 per share, totaling approximately $633,800.
• On December 17, 2025, 25,744 shares were sold at a weighted average price of $22.1595 per share, totaling approximately $570,300.
• These transactions were non-discretionary, executed by the issuer on Mr. Rosen's behalf to cover tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs).
• The sales were made pursuant to an equity administration policy implemented on May 22, 2025, and a Rule 10b5-1(c) plan.
• Following these transactions, Mr. Rosen beneficially owns 2,194,809 shares of common stock.
• His beneficial ownership includes 236 shares purchased on November 30, 2025, through the Company's Employee Stock Purchase Plan and unvested RSU grants.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While shares were sold, it was a non-discretionary transaction for tax purposes following RSU vesting, which is a positive event for the executive. It does not indicate a lack of confidence in the company.

Positives

• The sales were non-discretionary and for tax withholding, indicating that RSU vesting occurred, which is a positive event for the executive.
• The transactions were executed under a Rule 10b5-1(c) plan, demonstrating pre-planned compliance and transparency in insider trading.

Negatives

• The CEO's direct beneficial ownership of common stock decreased by 54,691 shares as a result of these sales.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on May 22, 2025, and does not represent a discretionary trade by the reporting person.

Industry Context

Insider transaction reports like Form 4 are routine disclosures for publicly traded companies, detailing changes in beneficial ownership by executives and directors. Sales for tax withholding upon RSU vesting are a common occurrence in executive compensation structures across various industries, particularly in biotechnology where equity compensation is prevalent.

Corporate Governance

Stakeholder Impact

• Shareholders: The reduction in the CEO's direct beneficial ownership is minor in the context of his overall holdings and is a routine, non-discretionary event, unlikely to signal any change in management's confidence.
• Employees: The RSU vesting and subsequent tax-related sale are part of standard equity compensation practices, which can be a positive for employee morale and retention.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary sale of shares by the CEO to cover tax obligations upon RSU vesting. Such transactions are common and pre-scheduled under a 10b5-1 plan, and do not typically reflect a change in the executive's outlook on the company's prospects. Therefore, this filing does not provide new fundamental information that would warrant a change in investment recommendation; a 'hold' stance is maintained based on existing company fundamentals.

Keywords

Arcus Biosciences, RCUS, Form 4, Insider Transaction, CEO Stock Sale, RSU Vesting, Tax Withholding, Equity Compensation, Rule 10b5-1 Plan